Literature DB >> 16054732

Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children.

Vana I Spoulou1, Dimitris L Tsoumas, Vana G Papaevangelou, Glykeria I Mostrou, Maria C Theodoridou.   

Abstract

A 7-valent CRM197 conjugate pneumococcal vaccine (PCV)-induced immune response were evaluated in all Greek symptomatic HIV-1 infected children and 21 age-matched controls. PCV immunogenicity was inferior in HIV patients compared with the controls although differences in geometric mean concentrations (GMC) were not significant (P>.05). Immune responses were strikingly different after anamnestic immunization, given in all study subjects, 12 months later. HIV-positive children achieved lower GMC for all serotypes compared with the controls (P=.002) and avidity for all except serotype 6B was inferior compared to baseline. Long-term PCV effectiveness is expected to be reduced among symptomatic HIV-1 infected children.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054732     DOI: 10.1016/j.vaccine.2005.06.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Conjugate vaccines and polysaccharide response.

Authors:  Sujoy Khan
Journal:  CMAJ       Date:  2006-03-28       Impact factor: 8.262

Review 2.  Anti-pneumococcal antibody titre measurement: what useful information does it yield?

Authors:  Paul Balmer; Andrew J Cant; Ray Borrow
Journal:  J Clin Pathol       Date:  2006-09-01       Impact factor: 3.411

Review 3.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.

Authors:  Solen Kernéis; Odile Launay; Clément Turbelin; Frédéric Batteux; Thomas Hanslik; Pierre-Yves Boëlle
Journal:  Clin Infect Dis       Date:  2014-01-10       Impact factor: 9.079

4.  Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Authors:  Mark J Abzug; Lin Ye Song; Myron J Levin; Sharon A Nachman; William Borkowsky; Stephen I Pelton
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

Review 5.  Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability.

Authors:  Carl T D'Angio
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 6.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

7.  Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis.

Authors:  Hossein Molavi Vardanjani; Hodjat Borna; Ali Ahmadi
Journal:  BMC Infect Dis       Date:  2019-08-05       Impact factor: 3.090

8.  Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.

Authors:  Alasdair Bamford; Peter Kelleher; Hermione Lyall; Mitch Haston; Marta Zancolli; David Goldblatt; Beate Kampmann
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.